Эпидемиологические особенности рака предстательной железы в Дальневосточном федеральном округе
Background. Recent decades in the Far East Federal District have been characterized by a constant increase in the number of patients with oncological pathology, in the structure of which prostate tumors are the second largest cause of mortality in men. The goal of this study was a scientific assessment of the main rates of morbidity and mortality of prostate cancer in the male population in the Far East Federal District for the last ten years (2009–2018). Material and methods. During the study, the indicators of morbidity and mortality, reporting forms of statistical registration of oncological patients and regulatory documents of higher-level organizations, information on ten-year observations of the dynamics of changes in digital indicators of the investigated pathology were used. Results of the research. The main rates of morbidity and mortality of prostate cancer patients in the Far East Federal District are given, where 33,111 new cases of malignant neoplasms were registered in 2018, that is 24,6 % higher than ten years ago (20 191 people in 2009). In Russia, such increase was 21,6 % higher. 9 324 patients, i.e. 0,12 % population of the region, were under medical supervision. The number of patients with I-II stages of the disease (60,9 %) increased during the investigated period with simultaneous reduction of the number of patients with neglected forms (38,1 %) of the disease. Morbidity and mortality rates have been increasing steadily over the past 10 years. The percentage of actively identified patients has increased, as well as the year-end accumulation index. Morphological confirmation of the diagnosis (over 95 %) did not exceed the average republican indicators (95,9 %). The proportion of patients registered for 5 years or more was lower than averagely in Russia, but mortality rates improved in the first year from the time of the initial diagnosis (2009 – 17,3 %; 2018 – 10,1 %; Russian Federation – 7,8 %). As far as the localizations in the male reproductive organs, neglected prostate cancer remains at the highest level.